214 related articles for article (PubMed ID: 1456398)
1. Mass screening of neuroblastoma in Sapporo City, Japan.
Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
[TBL] [Abstract][Full Text] [Related]
2. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
3. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of screening for neuroblastoma in the north of England.
Craft AW; Parker L; Dale G; McGill AC; Seviour JA; Bell S; Cole M; Smith J
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):337-41. PubMed ID: 1456400
[TBL] [Abstract][Full Text] [Related]
5. Cases of neuroblastoma missed by the mass screening programs.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
[TBL] [Abstract][Full Text] [Related]
6. Results of mass screening for neuroblastoma in Sapporo, Japan.
Takeda T; Nishi M; Shimada M; Nakadate H; Hatae Y; Naito H; Hanai J; Kawai T; Takasugi N
Prog Clin Biol Res; 1991; 366():595-601. PubMed ID: 2068178
[No Abstract] [Full Text] [Related]
7. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
8. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
9. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
10. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
11. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
12. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
[TBL] [Abstract][Full Text] [Related]
13. Mass screening for neuroblastoma targeting children age 14 months in Sapporo City: a preliminary report.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Hirama T
Cancer; 1998 May; 82(10):1973-7. PubMed ID: 9587132
[TBL] [Abstract][Full Text] [Related]
14. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
[TBL] [Abstract][Full Text] [Related]
15. Seasonal variations in vanillylmandelic acid and homovanillic acid in infants' urine.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Jun; 17(2):151-5. PubMed ID: 3613139
[TBL] [Abstract][Full Text] [Related]
16. Treatment complications in children diagnosed with neuroblastoma during a screening program.
Barrette S; Bernstein ML; Leclerc JM; Champagne MA; Samson Y; Brossard J; Woods WG
J Clin Oncol; 2006 Apr; 24(10):1542-5. PubMed ID: 16575005
[TBL] [Abstract][Full Text] [Related]
17. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.
Tanaka M; Kigasawa H; Kato K; Ijiri R; Nishihira H; Aida N; Ohama Y; Tanaka Y
Pediatr Blood Cancer; 2010 Apr; 54(4):573-8. PubMed ID: 20049932
[TBL] [Abstract][Full Text] [Related]
19. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
20. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
